# ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)

> **NCT03602560** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 265 (actual)

## Conditions studied

- Primary Biliary Cholangitis

## Interventions

- **DRUG:** seladelpar 5-10 mg
- **DRUG:** seladelpar 10 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03602560
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-01
- **Primary completion:** 2020-02-16
- **Final completion:** 2020-02-16
- **Target enrollment:** 265 (ACTUAL)
- **Last updated:** 2022-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03602560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03602560, "ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03602560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*